Mpox in children and adolescents and contact follow-up in school settings in greater Paris, France, May 2022 to July 2023
- PMID: 38785093
- PMCID: PMC11128737
- DOI: 10.2807/1560-7917.ES.2024.29.21.2300555
Mpox in children and adolescents and contact follow-up in school settings in greater Paris, France, May 2022 to July 2023
Abstract
BackgroundDuring the 2022 mpox outbreak in Europe, primarily affecting men who have sex with men, a limited number of cases among children and adolescents were identified. Paediatric cases from outbreaks in endemic countries have been associated with a higher likelihood of severe illness. Detailed clinical case descriptions and interventions in school settings before 2022 are limited.AimTo describe clinical characteristics of mpox cases among children (< 15 years) and adolescents (15-17 years) in the greater Paris area in France, and infection control measures in schools.MethodsWe describe all notified laboratory-confirmed and non-laboratory-confirmed cases among children and adolescents identified from May 2022 to July 2023, including demographic and clinical characterisation and infection control measures in school settings, i.e. contact tracing, contact vaccination, secondary attack rate and post-exposure vaccination uptake.ResultsNineteen cases were notified (13 children, 6 adolescents). Four adolescent cases reported sexual contact before symptom onset. Ten child cases were secondary cases of adult patients; three cases were cryptic, with vesicles on hands, arms and/or legs and one case additionally presented with genitoanal lesions. Five cases attended school during their infectious period, with 160 at-risk contacts identified, and one secondary case. Five at-risk contacts were vaccinated following exposure.ConclusionCases among children and adolescents are infrequent but require a careful approach to identify the source of infection and ensure infection control measures. We advocate a 'contact warning' strategy vs 'contact tracing' in order to prevent alarm and stigma. Low post-exposure vaccination rates are expected.
Keywords: Mpox; contact tracing; paediatric; surveillance; vaccination.
Conflict of interest statement
Figures
References
-
- Vaughan AM, Cenciarelli O, Colombe S, Alves de Sousa L, Fischer N, Gossner CM, et al. A large multi-country outbreak of monkeypox across 41 countries in the WHO European Region, 7 March to 23 August 2022. Euro Surveill. 2022;27(36):2200620. 10.2807/1560-7917.ES.2022.27.36.2200620 - DOI - PMC - PubMed
-
- Santé publique France (SpF). Monkeypox 2023. Paris: Santé Publique France [Accessed: 5 Sep 2023]. Available from: https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-tra...
-
- Haute Autorité de Santé (HAS). Avis n°2022.0034/SESP du 20 mai 2022 du collège de la Haute Autorité de santé relatif à la vaccination contre le virus Monkeypox. [High Authority of Health advice n°2022.0034/SESP of May 20, 2022 relating to vaccination against mpox virus]. Saint-Denis La Plaine: HAS; 2022. French. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2022-05/avis_n2022....
-
- Haute Autorité de Santé. Monkeypox: la stratégie vaccinale réactive précisée pour les primo-vaccinés et les enfants. [Monkeypox: the reactive vaccine strategy specified for non-vaccinated adults and children]. Paris: Haute Autorité de Santé; 2022. French. Available from: https://www.has-sante.fr/jcms/p_3345056/fr/monkeypox-la-strategie-vaccin...
MeSH terms
LinkOut - more resources
Full Text Sources